研究单位：[1]Tasly Biopharmaceuticals Co., Ltd.[2]Beijing Luhe Hospital,Capital Medical University,Beijing, Beijing, China[3]XuanWu Hospital, Capital Medical University,Beijing, Beijing, China[4]Liuzhou Worker's Hospital,Liuzhou, Guangxi, China[5]Cangzhou Central Hospital,Cangzhou, Hebei, China[6]The First Hospital of Handan,Handan, Hebei, China[7]Harrison International Peace Hospital,Hengshui, Hebei, China[8]The First Hospital of Hebei Medical University,Shijiazhuang, Hebei, China[9]The Second Hospital of Hebei Medical University,Shijiazhuang, Hebei, China[10]Tangshan Gongren Hospital,Tangshan, Hebei, China[11]Daqing Oilfield General Hospital,Daqing, Heilongjiang, China[12]The First Affiliated Hospital of Harbin Medical University,Harbin, Heilongjiang, China[13]The Fourth Affiliated Hospital of Harbin Medical University,Harbin, Heilongjiang, China[14]The First Hospital of Changsha,Changsha, Hunan, China[15]First Affiliated Hospital of Baotou Medical College,Baotou, Inner Mongolia, China, 100053[16]Baotou Central Hospital,Baotou, Inner Mongolia, China[17]Affiliated Hospital of Inner Mongolia Medical University,Hohhot, Inner Mongolia, China[18]Inner Mongolia People's Hospital,Hohhot, Inner Mongolia, China[19]Huai'an First People's Hospital,Huai'an, Jiangsu, China[20]The Second People'Hospital of Huai'an,Huai'an, Jiangsu, China[21]Nanjing Drum Tower Hospital,Nanjing, Jiangsu, China[22]The Affiliated Hospital of Xuzhou Medical University,Xuzhou, Jiangsu, China[23]Xuzhou Central Hospital,Xuzhou, Jiangsu, China[24]Jiangxi Pingxiang People's Hospital,Pingxiang, Jiangxi, China[25]First Hospital of Jilin University,Changchun, Jilin, China[26]The Neuropsychiatric Hospital of Jilin Province,Siping, Jilin, China[27]Dalian Municipal Central Hospital,Dalian, Liaoning, China[28]Shenyang Military Region General Hospital,Shenyang, Liaoning, China[29]The 163th Hospital of the Chinese People's Liberation Army,Shenyang, Liaoning, China[30]Liaocheng People's Hospital,Liaocheng, Shandong, China[31]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an, Shanxi, China[32]The People's Hospital of Sichuan Province,Chengdu, Sichuan, China[33]Deyang people's hospital,Deyang, Sichuan, China[34]Tianjin Huanhu Hospital,Tianjin, Tianjin, China[35]Taizhou Hospital of Zhejiang Province,Taizhou, Zhejiang, China[36]Luoyang Central Hospital,Luoyang, Zhengzhou, China
研究目的：
This is a randomized, rt-PA controlled, open-label phase 3 clinical study to evaluate the efficacy and safety of recombinant human urokinase(rhPro-UK) versus rt-PA thrombolysis for patients with acute ischaemic stroke in 4.5 hours after stroke onset.
